+

WO2002019964A2 - Procedes et compositions pharmaceutiques utilisant la desmethylselegiline pour traiter des maladies ou des etats neoplasiques - Google Patents

Procedes et compositions pharmaceutiques utilisant la desmethylselegiline pour traiter des maladies ou des etats neoplasiques Download PDF

Info

Publication number
WO2002019964A2
WO2002019964A2 PCT/US2001/026658 US0126658W WO0219964A2 WO 2002019964 A2 WO2002019964 A2 WO 2002019964A2 US 0126658 W US0126658 W US 0126658W WO 0219964 A2 WO0219964 A2 WO 0219964A2
Authority
WO
WIPO (PCT)
Prior art keywords
dms
selegiline
condition
mao
composition
Prior art date
Application number
PCT/US2001/026658
Other languages
English (en)
Other versions
WO2002019964A3 (fr
Inventor
Cheryl D. Blume
Anthony R. Disanto
Original Assignee
Somerset Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somerset Pharmaceuticals, Inc. filed Critical Somerset Pharmaceuticals, Inc.
Priority to CA002420993A priority Critical patent/CA2420993A1/fr
Priority to AU8679801A priority patent/AU8679801A/xx
Priority to AU2001286798A priority patent/AU2001286798B2/en
Publication of WO2002019964A2 publication Critical patent/WO2002019964A2/fr
Publication of WO2002019964A3 publication Critical patent/WO2002019964A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Definitions

  • the present invention pertains to methods and pharmaceutical compositions for using the selegiline metabolite R(-) desmethylselegiline (also referred to simply as “desmethylselegiline” or “R(-)DMS”) alone; its enantiomer ent-desmethylselegiline (also referred to as “S(+)desmethylselegiline” or “S(+)DMS”) alone; or a combination, such as, for example, aracemic mixture, of the two enantiomers.
  • the present invention provides compositions and methods for using these agents in the treatment of selegiline-responsive diseases and conditions, particularly diseases or conditions involving neoplastic cells, such as cancerous cells, or those cells that proliferate for no physiologically advantageous purpose.
  • monoamine oxidase A MAO- A
  • monoamine oxidase B MAO-B
  • the cDNAs encoding these enzymes show different promoter regions and distinct exon portions, indicating they are encoded independently at different gene positions.
  • analysis of the two proteins has shown differences in their respective amino acid sequences.
  • the first compound found to selectively inhibit MAO-B was (R)-N- ⁇ -dimethyl-N-2- propynylbenzeethanamine, also known as E-(-)-N- ⁇ -N-2-propynylphenethylamine, (-)-deprenil, L-(-)-deprenyl, R-(-)-deprenyl, or selegiline. Selegiline has the following structural formula:
  • Selegiline is the active ingredient of a human drug product and is known in the art as a component of a therapeutic package.
  • Physicians Desk Reference (1995) pp. 2430-2432 (1995 PDR) describing Eldepryl® Tablets, manufactured by Somerset Pharmaceutical, Inc. and marketed by Sandoz, the active ingredient of which is selegiline.
  • the 1995 PDR describes a 5 mg selegiline hydrochloride tablet and further describes the manner in which selegiline-containing therapeutic packages are supplied for commercial use or sale.
  • the 1995 PDR discloses that 5.0 mg Eldepryl Tablets are sold in "NDC 39506-011-25 bottles of 60 tablets.”
  • selegiline-containing therapeutic packages are labeled and otherwise indicated for use in Parkinsonian patients receiving levodopa/carbidopa therapy.
  • the 1995 PDR cited above provides an example of the complete approved labeling that is employed in known therapeutic packages.
  • known in the prior art are therapeutic packages providing one or more unit doses of selegiline as an active ingredient thereof, supplied in a finished pharmaceutical container that contains said unit doses, and further contains or comprises labeling directing the use of said package in the treatment of a human disease or condition as described above.
  • Parkinson's disease In addition to Parkinson's disease, other diseases and conditions for which selegiline is disclosed as being useful include: drug withdrawal (WO 92/21333, including withdrawal from psychostimulants, opiates, narcotics, and barbiturates); depression (U.S. patent 4,861,800); Alzheimer's disease and Parkinson's disease, particularly through the use of transdermal dosage forms, including ointments, creams and patches; macular degeneration (U.S. patent 5,242,950); age-dependent degeneracies, including renal function and cognitive function as evidenced by spatial learning ability (U.S patent 5,151,449); pituitary-dependent Cushing's disease in humans and nonhumans (U.S.
  • Selegiline is known to be useful when administered to a subject through a wide variety of routes of administration and dosage forms.
  • U.S. patent 4,812,481 discloses the use of concomitant selegiline-amantadine in oral, peroral, enteral, pulmonary, rectal, nasal, vaginal, lingual, intravenous, intraarterial, intracardial, intramuscular, intraperitoneal, intracutaneous, and subcutaneous formulations.
  • U.S. patent 5,192,550 (Alza Corporation) describes a dosage form comprising an outer wall impermeable to selegiline but permeable to external fluids.
  • This dosage form may have applicability for the oral, sublingual or buccal administration of selegiline.
  • U.S. patent 5,387,615 discloses a variety of selegiline compositions, including tablets, pills, capsules, powders, aerosols, suppositories, skin patches, parenterals, and oral liquids, including oil-aqueous suspensions, solutions, and emulsions. Also disclosed are selegiline-containing sustained release (long acting) formulations and devices.
  • the selectivity of selegiline in the inhibition of MAO-B is important to its safety profile following oral administration.
  • Inhibition of MAO-A in peripheral sites may cause toxic side effects by interfering with the metabolism of tyramine.
  • Tyramine is normally metabolized in the gastrointestinal tract by MAO-A but when MAO-A is inhibited, tyramine absorption is increased following consumption of tyramine-containing foods such as cheese, beer, herring, etc. This results in the release of catecholamines which can precipitate a hypertensive reaction, producing the "cheese effect.” This effect is characterized by Goodman and Gilman as the most serious toxic effect associated with MAO-A inhibitors.
  • Selegiline is metabolized into its N-desmethyl analog (and their various potentially harmful methamphetamines). Structurally, this N-desmethyl metabolite is the R(-) enantiomeric form R(-)DMS of a secondary amine of the formula:
  • R(-)DMS was not known to have pharmaceutically useful MAO-related effects, i.e., potent and selective inhibitory effects on MAO-B.
  • MAO-related effects of R(-)DMS were more completely characterized. This characterization has established that desmethylselegiline has exceedingly weak MAO-B inhibitory effects and no advantages in selectivity with respect to MAO-B compared to selegiline.
  • the present characterization established that selegiline has an IC 5 o value against MAO-B in human platelets of 5 x 10 "9 M whereas R(-)DMS has an IC 50 value of 4 x 10 "7 M, indicating the latter is approximately 80 times less potent as an MAO-B inhibitor than the former. Similar characteristics can be seen in the following data measuring inhibition of MAO-B and MAO-A in rat cortex mitochondrial-rich fractions:
  • R(-)DMS as an MAO-B inhibitor provides no advantages in either potency or selectivity compared to selegiline. Indeed, the above in vitro data suggest that use of R(-)DMS as an MAO-B inhibitor requires on the order of 70 times the amount of selegiline.
  • R(-)DMS in vivo has only about one-fifth the MAO-B inhibitory effect of selegiline, i.e., a dose of 10 mg of desmethylselegiline would be required for the same MAO-B effect as 1.8 mg of selegiline.
  • R(-)DMS In rats, Borbe reported R(-)DMS to be an irreversible inhibitor of MAO-B, with a potency about 60 fold lower than selegiline in vitro and about 3 fold lower ex vivo (Barbe, H.O., J Neural Trans. (Suppl.):32:131 (1990)).
  • R(-)DMS is a less-preferred, less effective MAO inhibitor than selegiline and therefore a less desirable therapeutic compound.
  • the present invention is based upon the surprising discovery that R(-)DMS and its enantiomer S(+)DMS, having the following structure:
  • R(-)DMS, S(+)DMS, and combinations such as racemic mixtures of the two provide a more advantageous way of obtaining selegiline therapeutic effects in selegiline-responsive diseases or conditions. This is particularly true for diseases or conditions characterized by neoplastic cells such as, for example, cancerous cells, or cells that proliferate in an unregulated manner.
  • the present invention provides novel pharmaceutical compositions in which R(-)DMS, S(+)DMS, or a combination, such as a racemic mixture, of the two is employed as the active ingredient. Also provided are novel therapeutic methods involving the administration of such compositions. More specifically, the present invention provides:
  • a pharmaceutical composition comprising an amount of R(-)DMS, S(+)DMS, or a combination of the two, such that one or more unit doses of said composition administered on a periodic basis is effective to treat one or more neoplastic diseases or conditions in a subject to whom said unit dose or unit doses are administered.
  • This composition may be formulated for non-oral or oral administration.
  • a method of treating a neoplastic condition in a subject which comprises administering to said mammal R(-)DMS, S(+)DMS, or a combination of the two, in a dosage regimen effective to produce a selegiline therapeutic effect, such as a daily dose, administered in a single or multiple dosage regimen of at least about 0.0015 mg, calculated on the basis of the free secondary amine, per kg. of the mammals body weight.
  • a transdermal delivery system for use in treating a neoplastic condition in a mammal which comprises a layered composite of one or more layers with at least one layer including an amount of R(-)DMS, S(+)DMS, or a combination of the two sufficient to supply a daily transdermal dose of at least about 0.0015 mg of the free secondary amine, per kg of the mammal's body weight; and
  • a therapeutic package for dispensing to, or for use in dispensing to, a patient being treated for a neoplastic disease or condition contains one or more unit doses, each such unit dose comprising an amount of R(-)DMS, S(+)DMS or a combination of the two, such that periodic administration is effective in treating the patient's neoplastic disease or condition.
  • the therapeutic package also comprises a finished pharmaceutical container containing the unit doses of R(-)DMS, S(+)DMS, or combination thereof, and further containing or comprising labeling directing the use of the package in the treatment of the neoplastic disease or condition.
  • the unit doses may be adapted for oral administration, e.g. as tablets or capsules, or may be adapted for non-oral administration.
  • a method of dispensing R(-)DMS, S(+)DMS, or a combination of the two, to a patient being treated for a neoplastic disease or condition comprises providing patients with a therapeutic package having one or more unit doses of desmethylselegiline, ent- desmethylselegeline or a mixture of the two, in an amount such that periodic administration to the patient is effective in treating their selegiline-responsive neoplastic disease or condition.
  • the package also comprises a finished pharmaceutical container containing the desmethylselegiline, ent- desmethylselegeline, or a mixture of the two, and having labeling directing the use of the package in the treatment the selegiline-responsive neoplastic disease or condition.
  • the unit doses in the package may be adapted for either oral or non-oral.
  • Preferred embodiments of the present disclosure are methods for obtaining a selegiline therapeutic effect in a patient with a neoplastic disease or condition, by administering to the patient R(-)DMS, S(+)DMS, or a mixture of R(-)DMS and S(+)DMS.
  • the patient is amammal, more preferably a human or a domesticated animal.
  • the R(-)DMS, S(+)DMS, or a mixture of both enantiomers is preferably administered in a dosage regimen effective to suppress or -Lr-hibit, in whole or in part, occurrence, reoccurrence, or progression of the neoplastic disease or condition.
  • R(-)DMS or S(+)DMS is administered in a substantially enantiomerically pure form.
  • R(-)DMS and/or S(+)DMS are administered as the free base or as an acid addition salt.
  • the acid addition salt is hydrochloride salt.
  • the neoplastic disease or condition treated by administering R(-)DMS, S(+)DMS, or a combination of the two is a mammary tumor or a pituitary tumor.
  • R(-)DMS, S(+)DMS, or a mixture of both enantiomers is administered at a daily dose of between about 0.02 mg/kg and about 5.0 mg/kg, more preferably at a daily dose of between about 0.6 mg/kg and about 0.8 mg/kg, calculated on the basis of the free secondary amine.
  • the R(-)DMS, S(+)DMS, or a combination of the two is administered by an oral route of administration, or a non-oral route of administration.
  • Non-oral routes of administration preferably include sublingual, buccal, parenteral, or transdermal administration.
  • R(-)DMS, S(+)DMS, or a combination of the two is administered by a transdermal patch.
  • Another preferred embodiment of the present disclosure is a pharmaceutical composition that includes R(-)DMS, S(+)DMS, or a mixture of R(-)DMS and S(+)DMS, as well as a second therapeutic agent useful in the treatment of a neoplastic disease or condition.
  • one or more therapeutic agents are included in the pharmaceutical composition.
  • the R(-)DMS, S(+)DMS, or mixture of R(-)DMS and S(+)DMS, and the second therapeutic agent are present in the pharmaceutical composition in an amount such that one or more unit doses of the composition are effective to suppress or inhibit, in whole or in part, progression of the neoplastic disease or condition.
  • R(-)DMS and/or S(+)DMS are administered as the free base or as an acid addition salt.
  • the acid addition salt is hydrochloride salt.
  • the neoplastic disease or condition treated by a pharmaceutical composition with R(-)DMS, S(+)DMS, or a combination of the two, and a second therapeutic agent is a mammary tumor or a pituitary tumor.
  • the second therapeutic agent is an anti-neoplastic agent or a chemotherapeutic agent.
  • the anti-neoplastic agent is tamoxifen, cisplatin, paclitaxel, or methotrexate.
  • the second therapeutic agent is a radiation implant.
  • the R(-)DMS, S(+)DMS, or combination of the two enantioners in a unit dose of the pharmaceutical composition is between about 0.02 and about 5.0 mg/kg, more preferably between about 0.6 and about 0.8 mg/kg, calculated on the basis of the free secondary amine.
  • the R(-)DMS, S(+)DMS, or combination of the two enantioners in a unit dose of the pharmaceutical composition is between about 1.0 mg and about 100.0 mg, more preferably between about 5.0 mg and about 10.0 mg.
  • the pharmaceutical composition is for oral administration, for non-oral administration, or for transdermal administration.
  • the pharmaceutical composition is a transdermal patch.
  • Preferred embodiments of the present disclosure are also directed to methods for obtaining a selegiline therapeutic effect in a patient with a neoplastic disease or condition, by administering to the patient a pharmaceutical composition that includes R(-)DMS, S(+)DMS, or a mixture of R(-)DMS and S(+)DMS, as well as a second therapeutic agent useful in the treatment of a neoplastic disease or condition.
  • a pharmaceutical composition that includes R(-)DMS, S(+)DMS, or a mixture of R(-)DMS and S(+)DMS, as well as a second therapeutic agent useful in the treatment of a neoplastic disease or condition.
  • one or more unit doses of the pharmaceutical composition are effective to suppress or inhibit, in whole or in part, occurrence, reoccurrence, or progression of the neoplastic disease or condition.
  • kits for obtaining a selegiline therapeutic effect in a patient with a neoplastic disease or condition by administering to the patient R(-)DMS, S(+)DMS, or a mixture of R(-)DMS and S(+)DMS in combination with a second therapy useful in the treatment of a neoplastic disease or condition, in a dosage regimen effective to suppress or inhibit, in whole or in part, occurrence, reoccurrence, or progression of the neoplastic disease or condition.
  • the second therapy is chemotherapy or radiation.
  • FIG. 1 HPLC Chromatogram of Purified R(-)DMS (Microsorb MV Cyano Column). The purity of a preparation of R(-)DMS was determined by HPLC on a Microsorb MV Cyano column and results are shown in Figure 1.
  • the column had dimensions of 4.6 mm X 15 cm. and was developed at a flow rate of 1.0 ml/min using a mobile phase containing 90% 0.01 M H 3 PO 4 (pH 3.5) and 10% acetonitrile.
  • the column was run at a temperature of 40°C and effluent was monitored at a wavelength of 215 nm.
  • the chromatogram shows one major peak appearing at a time of 6.08 minutes and having 99.5% of the total light-absorbing material eluted from the column. No other peak had greater than 0.24%.
  • Figure 2 HPLC Elution Profile of R(-)DMS (Zorbax Mac-Mod C 18 Column). The same preparation that was analyzed in the experiments discussed in Figure 1 was also analyzed for purity by HPLC on a Zorbax Mac-Mod SB-C18 column (4.6 mm X 75 mm). Effluent was monitored at 215 nm and results can be seen in Figure 2. Greater than 99.6% of the light-absorbing material appeared in the single large peak eluting at a time of between 2 and 3 minutes.
  • Figure 3 Mass Spectrum of R(-)DMS. A mass spectrum was obtained for purified R(-)DMS and results are shown in Figure 3. The spectrum is consistent with a molecule having a molecular weight of 209.72 amu and a molecular formula of C 12 H 15 N-HC1.
  • Figure 4 Infrared Spectrum. (KBr) of Purified R(-)DMS. Infrared spectroscopy was performed on a preparation of R(-)DMS and results are shown in Figure 4. The solvent used was CDC1 3 .
  • Figure 5 NMR Spectrum of Purified R(-)DMS. A preparation of purified R(-)DMS was dissolved in CDC1 and 1H NMR spectroscopy was performed at 300 nm. Results are shown in Figure 5.
  • Figure 6 HPLC Chromatogram of S(+)DMS. The purity of a preparation of S(+)DMS was examined by reverse phase HPLC on a 4.6 min X 75 min Zorbax Mac-Mod SB-C18 column. The elution profile, monitored at 215 nm, is shown in Figure 6. One major peak appears in the profile at a time of about 3 minutes and contains greater than 99% of the total light-absorbing material that eluted from the column.
  • Figure 7 Mass Spectrum of Purified S(+)DMS. Mass spectroscopy was performed on the same preparation examined in Figure 6. The spectrum is shown in Figure 7 and is consistent with the structure of S(+)DMS.
  • Figure 8 Infrared Spectrum (KBr) of Purified S(+)DMS. The preparation of S(+)DMS discussed in connection with Figures 6 and 7 was examined by infrared spectroscopy and results are shown in Figure 8.
  • Figure 9 Inhibition of Neuronal Dopamine Accumulation (Uptake) by Deprenyl and the Two Enantiomers of Desmethylselegiline. An in vitro nerve terminal preparation (synaptosome preparation) was prepared using fresh rat neostriatal tissue.
  • Figure 10 Determination of IC 50 Values for Inhibition of Dopamine Accumulation (Uptake). The experiment of Figure 9 was repeated in a concentration range designed to more accurately provide an IC 50 value and results are shown in Figure 10. Using the log C vs. probit graphs, as shown in the figure, the IC 50 for S(+)DMS was determined to be about 11 ⁇ M; for selegiline, about 46 ⁇ M; and for R(-)DMS about 54 ⁇ M.
  • FIG 11 In vivo MAO-B Inhibition in Guinea Pig Hippocampus.
  • Various doses of selegiline, R(-) desmethylselegiline, and S(+) desmethylselegiline were administered daily to guinea pigs for a period of 5 days. Animals were then sacrificed and the MAO-B activity in the hippocampus portion of the brain was determined. Results were expressed as a percent inhibition relative to hippocampus MAO-B activity in control animals and are shown in Figure 11. The plots were used to estimate the ID 50 dosage for each agent.
  • the ID 50 for selegiline was about 0.008 mg/kg; for R(-)DMS, it was about 0.2 mg/kg; and for S(+)DMS, it was about 0.5 mg/kg.
  • the term "selegiline-responsive disease or condition” refers to any of the various diseases or conditions in mammals, including humans, for which selegiline is known as being therapeutically useful, such as, for example, the various diseases and conditions described above, e.g., Parkinson's disease, cognitive dysfunction, neuronal rescue, neoplastic diseases, and the like.
  • the term "selegiline therapeutic effect” refers to one or more of the salutary effects reported as being exerted by selegiline in subjects being treated for a selegiline-responsive disease or condition.
  • neoplastic disease or condition refers to any type of disease or condition such as, but not limited to, any known selegiline-responsive neoplasms, any malignant or benign neoplasms, including any type of diffuse neoplasm such as leukemia, as well as malignant or benign cancers and tumors (including any carcinoma, sarcoma, or adenoma).
  • a neoplasm is abnormal tissue that grows by cellular proliferation more rapidly than normal, and can continue to grow after the stimuli that initiated the new growth has ceased.
  • a neoplasm may also have partial or complete lack of structural organization and functional coordination with normal tissue.
  • neoplastic diseases or conditions are, for example, tumors such as tumors of the mammary, pituitary, thyroid, or prostate gland; tumors of the brain, liver, meninges, bone, ovary, uterus, cervix, and the like; as well as both monocytic and myelogenous leukemia.
  • neoplastic diseases or conditions include, but are not limited to, adenocarcinoma, adenoma, astrocytoma, bladder tumor, brain tumor, Burkitt lymphoma, breast carcinoma, cervical carcinoma, colon carcinoma, kidney carcinoma, liver carcinoma, lung carcinoma, ovarian carcinoma, pancreatic carcinoma, prostate carcinoma, rectal carcinoma, skin carcinoma, stomach carcinoma, testis carcinoma, thyroid carcinoma, chondrosarcoma, choriocarcinoma, fibroma, fibrosarcoma, glioblastoma, glioma, hepatoma, histiocytoma, leiomyoblastoma, leiomyosarcoma, lymphoma, liposarcoma cell, mammary tumor, medulloblastoma, myeloma, plasmacytoma, neuroblastoma, neuroglioma, osteogenic sarcoma, pancreatic tumor, pituitary tumor,
  • the present invention encompasses the inhibition, prevention, or suppression of neoplastic diseases or conditions by use of DMS in the form of R(-)DMS, S(+)DMS, or mixtures of R(-)DMS and S(+)DMS.
  • R(-)DMS means the R(-) enantiomeric form of DMS, including as a free base, as well as any acid addition salt thereof.
  • S(+)DMS encompasses the S(+) enantiomeric form of DMS, including as a free base, as well as any acid addition salt thereof.
  • Such salts of either R(-)DMS or S(+)DMS include those derived from organic and inorganic acids such as, without limitation, hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulphonic acid, acetic acid, tartaric acid, lactic acid, succinic acid, citric acid, malic acid, maleic acid, sorbic acid, aconitic acid, salicylic acid, phthalic acid, embonic acid, enanthic acid, and the like. Accordingly, reference herein to the administration of either or both R(-)DMS and S(+)DMS encompasses both the free base and acid addition salt forms.
  • R(-)DMS or S(+)DMS When either R(-)DMS or S(+)DMS is used alone in the presently disclosed compositions and methods, it is used in a substantially enantiomerically pure form.
  • Reference to mixtures or combinations of R(-)DMS and S(+)DMS includes both racemic and non-racemic mixtures of optical isomers.
  • neoplastic diseases or conditions will occur when either or both forms of DMS are administered to animals.
  • R(-)DMS and/or S(+)DMS will prevent or inhibit the occurrence or reoccurrence of a neoplastic disease or condition.
  • the neoplastic conditions or diseases treatable include but are not limited to, those listed above as selegiline-responsive neoplastic diseases or conditions. Because the use of R(-)DMS and/or S(+)DMS to promote healthy functioning of the immune system is also known (see related applications SN 679,330 and SN 679,328 (U.S. Patent No. 6,033,682)), the use of these substances to suppress or inhibit neoplastic disease conditions can be used simultaneously to improve immune system functioning during periods when it may be depressed due to other cancer chemotherapeutic regimens or other medical conditions.
  • R(-)DMS and/or S(+)DMS may be administered either by an oral route (involving gastrointestinal absorption) or by a non-oral route (does not rely upon gastrointestinal absorption, i.e. a route that avoids absorption of R(-)DMS and/or S(+)DMS from the gastrointestinal tract).
  • the DMS is administered in the form of the free base or as a physiologically acceptable non-toxic acid addition salt as described above.
  • the use of salts, especially the hydrochloride is particularly desirable when the route of administration employs aqueous solutions, as for example parenteral administration; use of delivered desmethylselegiline in the form of the free base is especially useful for transdermal administration.
  • R(-)DMS, S(+)DMS, or a mixture of both may be administered by the parenteral, topical, transdermal, intraocular, buccal, sublingual, intranasal, inhalation, vaginal, rectal or other routes as well.
  • the optimal daily dose of R(-)DMS, S(+)DMS, or of a combination, such as a racemic mixture, of R(-)DMS and S(+)DMS, useful for the purposes of the present invention is determined by methods known in the art, e.g., based on the severity of the disease or condition being treated, the condition of the subject to whom treatment is being given, the desired degree of therapeutic response, and the concomitant therapies being administered to the patient or animal. Ordinarily, however, the attending physician or veterinarian will administer an initial dose of at least about 0.015 mg/kg, calculated on the basis of the free secondary amine, with progressively higher doses being employed depending upon the route of administration and the subsequent response to the therapy.
  • the daily dose will be from about 0.02 mg/kg or 0.05 mg/kg to about 0.10 mg/kg or about 0.15 mg/kg to about 0.175 mg/kg or about 0.20 mg/kg or about 0.5 mg/kg and may extend to about 1.0 mg/kg or even 1.5, 2.0, 3.0 or 5.0 mg/kg of the patient's body weight depending on the route of administration.
  • Preferred daily doses will be in the range of about 0.10 mg kg to about 1.0 mg/kg. More preferred daily doses will be in the range of about 0.4 mg/kg to about 0.9 mg/kg. Even more preferred daily doses will be in the range of about 0.6 mg/kg to about 0.8 mg/kg. Again, all such doses should be calculated on the basis of the free secondary amine. These guidelines further require that the actual dose be carefully titrated by the attending physician or veterinarian depending on the age, weight, clinical condition, and observed response of the individual patient or animal.
  • Unit doses of pharmaceutical compositions that include R(-)DMS, S(+)DMS, or a mixture of R(-)DMS and S(+)DMS, are preferably between about 1.0 mg and about 100.0 mg, preferably between about 5.0 mg and about 80 mg, more preferably between about 10.0 mg and about 50.0 mg.
  • the unit dose of the pharmaceutical composition will be from about 0.02 mg or 0.05 mg to about 0.10 mg or about 0.15 mg to about 0.175 mg or about 0.20 mg or about 0.5 mg and may extend to about 1.0 mg or even to about 1.5 mg, 2.0 mg, 3.0 mg, 5.0 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg, or 250 mg.
  • any numerical values recited herein include all values from the lower value to the upper value in increments of one unit.
  • the amount of a component or a value of a process variable such as, for example, daily dose, unit dose, and the like is, for example, from 1 to 100, preferably from 5 to 80, more preferably from 10 to 50, it is intended that values such as 8 to 85, 22 to 68, 43 to 51 , 30 to 32, etc. are expressly enumerated in this disclosure.
  • one unit is considered to be 0.0001, 0.001, 0.01, or 0.1 as appropriate.
  • the daily dose can be administered in a single or multiple dosage regimen.
  • Either oral or non-oral dosage forms may be used and may permit, for example, a burst of the active ingredient from a single dosage unit, such as an oral composition, or a continuous release of relatively small amounts of the active ingredient from a single dosage unit, such as a transdermal patch, over the course of one or more days.
  • intravenous or inhalation routes may be preferred.
  • compositions containing one or both R(-)DMS or S(+)DMS can be prepared according to conventional techniques.
  • preparations for parenteral routes of administration e.g., intramuscular, intravenous and intraarterial routes, can employ sterile isotonic saline solutions.
  • Sterile buffered solutions can also be employed for intraocular administration.
  • Transdermal dosage unit forms of R(-)DMS and/or S(+)DMS can be prepared utilizing a variety of previously described techniques (see e.g., U.S. Patent Nos. 4,861,800; 4,868,218; 5,128,145; 5,190,763; and 5,242,950; and EP-A 404807, EP-A 509761, and EP-A 593807).
  • a monolithic patch structure can be utilized in which desmethylselegiline is directly incorporated into the adhesive and this mixture is cast onto a backing sheet.
  • R(-)DMS and/or S(+)DMS can be incorporated as an acid addition salt into a multilayer patch which effects a conversion of the salt to the free base, as described for example in EP-A 593807.
  • R(-)DMS or S(+)DMS can also be administered by a device employing a lyotropic liquid crystalline composition in which, for example, 5 to 15% of desmethylselegiline is combined with a mixture of liquid and solid polyethylene glycols, a polymer, and a nonionic surfactant, optionally with the addition of propylene glycol and an emulsifying agent.
  • a lyotropic liquid crystalline composition in which, for example, 5 to 15% of desmethylselegiline is combined with a mixture of liquid and solid polyethylene glycols, a polymer, and a nonionic surfactant, optionally with the addition of propylene glycol and an emulsifying agent.
  • Subjects treatable by the present preparations and methods include both human and non- human subjects. Accordingly, the compositions and methods above provide especially useful therapies for mammals, including humans, and in domesticated mammals. Thus, the present methods and compositions are used in treating neoplastic diseases or conditions in human, primate, canine, feline, bovine, equine, ovine, murine, caprine, and porcine species, and the like.
  • compositions and methods above require employment of an effective amount of R(-)DMS, S(+)DMS, or mixtures of the two.
  • R(-)DMS and its enantiomer appear to be at least as effective as selegiline in treating certain selegiline-responsive conditions, e.g., neoplastic diseases or conditions.
  • the present invention further encompasses the additional discovery that R(-)DMS, S(+)DMS, or combinations of the two (which are conveniently prepared by methods known in the art, as described in Example 1) may also be formulated with additional therapeutic agents, including but not limited to anti-neoplastic agents, chemotherapeutic agents, or even cocktails, to effectively treat a neoplastic disease or condition.
  • Additional therapeutic agents useful in the treatment of neoplastic diseases or conditions include, but are not limited to, tamoxifen, taxotere, doxorubicin, cisplatin, cyclophosphamide, paclitaxel, methotrexate, mechlorethamine, aldesleukin, altretamine, amsacrine, azacitidine, ifosfamide, melphalan, chlorambucil, hexamethylmelamine, thiotepa, triethylenethiophosphoramide, busulfan, carmustine, lomustine, semustine, streptozocin, dacarbazine, fluorouacil, floxuridine, fludarabine, goserelin, cytarabine, levamisole, mercaptopurine, iMoguanine, pentostatin, pipobroman, vinblastine, vincristine, vindesine, etoposide, tenipos
  • the present invention further encompasses methods for obtaining a selegiline therapeutic effect in a patient with a neoplastic disease or condition by administering to the patient a pharmaceutical composition that includes R(-)DMS, S(+)DMS, or combinations of the two (which are conveniently prepared by methods known in the art, as described in Example 1) and one or more additional therapeutic agents, including but not limited to anti-neoplastic agents, chemotherapeutic agents, or even cocktails, to effectively treat a neoplastic disease or condition.
  • Such pharmaceutical composition may also be used to inhibit, prevent, or suppress a neoplastic disease or condition.
  • the therapeutic agents used in combination with R(-)DMS, S(+)DMS, or a mixture of the two to treat a neoplastic disease or condition can also be presented to the patient in a separate formulation than the R(-)DMS, S(+)DMS, or racemic mixture.
  • separate administration of a therapeutic agent or even an administration which is spaced in time is contemplated by the present disclosure, particularly when the therapeutic agent and the DMS enantiomer or DMS enantiomers have a synergistic therapeutic action.
  • the present invention contemplates methods for obtaining a selegiline therapeutic effect in a patient with a neoplastic disease or condition by administering to the patient a pharmaceutical composition that includes R(-)DMS, S(+)DMS, or combinations of the two (which are conveniently prepared by methods known in the art, as described in Example 1) in combination with one or more additional treatments for neoplastic diseases or conditions, including but not limited to surgery, chemotherapy, radiation therapy, pharmacotherapy, gene therapy, and immunotherapy treatments.
  • Radiation therapy includes but is not limited to ionizing radiation; gamma radiation from radioactive isotopes such as cobalt-60, radium, radon, iridium, or electrically generated roentgen rays; radiation by external beam, implant, pellet, or seed; or variants thereof.
  • R(-)DMS, S(+)DMS, or combinations of the two may be administered to a patient before, during, and/or after other available treatments for neoplastic diseases or conditions. Additionally, separate administration of R(-)DMS, S(+)DMS, or a racemic mixture from the other treatments, or even an administration which is spaced in time, is contemplated by the present disclosure
  • R(-)DMS is prepared by methods known in the art.
  • desmethylselegiline is a known chemical intermediate for the preparation of selegiline as described in U.S. Patent No. 4,925,878.
  • Desmethylselegiline can be prepared by treating a solution of
  • reaction inert organic solvent such as toluene with an equimolar amount of a reactive propargyl halide such as propargyl bromide, Br-CH 2 -C ⁇ -CH, at slightly elevated temperatures (70°-90°C).
  • a reactive propargyl halide such as propargyl bromide, Br-CH 2 -C ⁇ -CH
  • the reaction can be conducted in the presence of an acid acceptor such as potassium carbonate.
  • the reaction mixture is then extracted with aqueous acid, for example 5% hydrochloric acid, and the extracts are rendered alkaline.
  • the nonaqueous layer which forms is separated, for example, by extraction with benzene, dried, and distilled under reduced pressure.
  • the propargylation can be conducted in a two-phase system of a water- immiscible solvent and aqueous alkali, utilizing a salt of R(+)-2-aminophenylpropane with a weak acid such as the tartrate, analogously to the preparation of selegiline as described in U.S. Patent No. 4,564,706.
  • S(+)DMS is conveniently prepared from the enantiomeric S(+)-2-aminophenylpropane (dextroamphetamine), i.e., following the procedures set forth above for desmethylselegiline.
  • N-(prop-2-ynyl)-2-aminophenylpropane in either optically active or racemic form can be converted to a physiologically acceptable non-toxic acid addition salt by conventional techniques such as treatment with a mineral acid.
  • a mineral acid for example, hydrogen chloride in isopropanol is employed in the preparation of desmethylselegiline hydrochloride.
  • Either the free base or salt can be further purified, again by conventional techniques such as recrystallization or chromatography.
  • a preparation of substantially pure R(-)DMS has the appearance of a white crystalline solid with a melting point of 162- 163 C and an optical rotation of [OCJ D 230 — 15.2 +/- 2.0 when measured at a concentration of 1.0 M using water as solvent.
  • R(-)DMS appeared to be 99.5% pure when analyzed by HPLC on a Microsorb MV Cyano column (see chromatogram in Figure 1) and 99.6% pure when analyzed by HPLC on a Zorbax Mac-Mod SB-C 18 column, (see chromatogram in Figure 2). No single impurity is present at a concentration greater than or equal to 0.5%.
  • Heavy metals are present at a concentration of less than 10 ppm and amphetamine hydrochloride at a concentration of less than 0.03 %.
  • the last solvents used for dissolving the preparation, ethyl acetate and ethanol are both present at a concentration of less than 0. 1 %.
  • a mass spectrum performed on the preparation (see Figure 3) is consistent with a compound having a molecular weight of 209.72 amu and a formula of C 12 H 15 NHC1. Infrared and NMR spectra are shown in Figures 4 and 5 respectively. These are also consistent with the known structure of R-(-)-DMS.
  • a preparation of substantially pure S(+)DMS has the appearance of a white powder with a melting point of approximately 160.04°C and a specific rotation of +15.1 degrees when measured at
  • the biological actions of the brain neurotransmitter dopamine are terminated at the synapse by a high-affinity, sodium and energy-dependent transport system (neuronal accumulation or uptake, formerly referred to as "re-uptake”) present within the limiting membrane of the presynaptic dopamine-containing nerve terminal. Inhibition of this transport mechanism would extend the actions of dopamine at the synapse and therefore enhance dopamine synaptic transmission.
  • DMS desmethylselegiline
  • the assay system used was essentially that described by Fang et al, (Neuropharmacology 33:763-768 (1994)).
  • An in vitro nerve-terminal preparation (symptosome-preparation) was obtained from fresh rat neostriatal brain tissue. Transport by dopamine nerve-terminals was estimated by measuring the uptake of tritiated dopamine.
  • Relative potency can be expressed in terms of the concentration required to inhibit dopamine uptake by 50% (IC50).
  • IC50 concentration required to inhibit dopamine uptake by 50%
  • Example 5 Actions of the R(-) and S(+) enantiomers of Desmethylselegiline (DMS) on Human Platelet MAO-B and Guinea Pig Brain MAO-B and MAO-A Activity
  • Human platelet MAO is comprised exclusively of the type-B isoform of the enzyme.
  • the in vitro and in vivo inhibition of this enzyme by the two enantiomers of DMS was determined and compared with inhibition due to selegiline.
  • the present study also examined the two enantiomers of DMS for inhibitory activity with respect to the MAO-A and MAO-B in guinea pig hippocampal tissue.
  • Guinea pig brain tissue is an excellent animal model for studying brain dopamine metabolism, the enzyme kinetics of the multiple forms of MAO and the inhibitory properties of novel agents that interact with these enzymes.
  • the multiple forms of MAO in this animal species show similar kinetic properties to those found in human brain tissue.
  • the test agents were administered to guinea pigs and the extent to which they might act as inhibitors of brain MAO in vivo was assessed.
  • the test system utilized the in vitro conversion of specific substrates of MAO-A ( 14 C-serotonin) in guinea pig hippocampal homogenates or MAO-B ( 14 C-phenylethylamine) by human platelets and guinea pig hippocampal homogenates.
  • the rate of conversion of each substrate was measured in the presence of S(+)DMS, R(-)DMS or selegiline and compared to the isozyme activity in the absence of these agents. A percent inhibition was calculated from these values. Potency was evaluated by comparing the concentration of each agent which caused a 50% inhibition(IC 5 o value).
  • Results for MAO-B inhibition are shown in Tables 5 and 6.
  • IC 50 values for MAO-B inhibition and potency as compared to selegiline is shown in Table 7.
  • Selegiline 5 nM(l) l nM (l) R(-)DMS 400 nM (80) 60 nM (60)
  • R(-)DMS was twice as potent as S(+)DMS as an MAO-A inhibitor and both were 20-40 times less potent than selegiline. Moreover, each of these agents were 2-3 orders of magnitude, i.e., 100 to 1000 times, less potent as inhibitors of MAO-A than inhibitors of MAO-B in hippocampal brain tissue. Therefore, selegiline and each enantiomer of DMS can be classified as selective MAO-B inhibitors in brain tissue.
  • Each enantiomer of DMS was administered in vivo by subcutaneous injection once a day for five consecutive days, and inhibition of brain MAO-B activity was then determined.
  • selegiline was found to have an ID 50 of 0.03 mg/kg; and both R(-)DMS and S(+)DMS were determined to be about 10 times less potent. More recent studies, performed on a larger group of animals, indicates that R(-)DMS is actually about 25 times less potent than selegiline as an inhibitor of MAO-B and that S(+)DMS is about 50 times less potent. Results are shown in Figure 11 and ID 50 values are summarized in Table 10.
  • Table 10 ID 50 Values for Brain MAO-B Following 5 Days of Administration
  • R(-)DMS and S(+)DMS both exhibit activity as MAO-B and MAO-A inhibitors. Each enantiomer was selective for MAO-B. S(+)DMS was less potent than R(-)DMS and both enantiomers of DMS were less potent than selegiline in inhibiting both MAO-A and MAO-B.
  • both enantiomers demonstrated activity in inhibiting MAO-B, indicating that these enantiomers are able to cross the blood-brain barrier.
  • the ability of these agents to inhibit MAO-B suggests that these agents may be of value as therapeutics for hypodopaminergic diseases such as ADHD and dementia.
  • Rats were administered saline or test agent ip, daily for 60 days. They were then maintained for an additional "wash out” period of 10 days during which time no treatment was given. At the end of this time, animals were sacrificed and their spleens were removed. The spleen cells were then assayed for a variety of factors which are indicative of immune system function. Specifically, standard tests were employed to determine the following:
  • IgM is a marker of B lymphocytes
  • CD5 is a marker of T lymphocytes
  • Table 11 shows, that there is a sharp decline in cellular interferon production that occurs with age.
  • Administration -of selegiline, R(-)DMS and S(+)DMS all led to a restoration of ⁇ -interferon levels with the most dramatic increases occurring at dosages of 1.0 mg/kg body weight.
  • Table 11 Effect of Age on T Cell Function*
  • Table 12 shows the extent to which R(-)DMS, S(+)DMS and selegiline are capable of restoring ⁇ -interferon production in the spleen cells of old rats.
  • Interferon- ⁇ is a cytokine associated with T cells that inhibit viral replication and regulate a variety of immunological functions. It influences the class of antibodies produced by B-cells, upregulates class I and class II MHC complex antigens and increases the efficiency of macrophage-mediated killing of infracellular parasites.
  • results obtained with respect to histological examination, the production of interferon, and the percentage of IgM positive spleen cells support the conclusion that the DMS enantiomers are capable of at least partially restoring the age-dependent loss of immune system function.
  • the results observed with respect to IFN- ⁇ are particularly important. In both humans and animals, IFN-y production is associated with the ability to successfully recover from infection with viruses and other pathogens.
  • R(-)DMS and S(+)DMS will have a therapeutically beneficial effect for diseases and conditions mediated by weakened host immunity. This would include AIDS, response to vaccines, infectious diseases and adverse immunological effects caused by cancer chemotherapy and cancer.
  • the two ingredients are thoroughly mixed, cast on a film backing sheet (e.g.,
  • Scotchpak® 9723 polyester The backing sheet is cut into patches a fluoropolymer release liner (e.g., Scotchpak® 1022) is applied, and the patch is hermetically sealed in a foil pouch.
  • a fluoropolymer release liner e.g., Scotchpak® 1022
  • One patch is applied daily to supply 1 - 10 mg of desmethylselegiline per 24 hours in the treatment of conditions in a human produced by neuronal degeneration or neuronal trauma.
  • Desmethylselegiline (0. 1 g) as the hydrochloride, 1.9 g of boric acid, and .004 g of phenyl mercuric nitrate are dissolved in sterile water qs 100 ml. The mixture is sterilized and sealed. It can be used ophthalmologically in the treatment of conditions produced by neuronal degeneration or neuronal trauma, as for example glaucomatous optic neuropathy and macular degeneration.
  • a 1 % solution is prepared by dissolving 1 g of desmethylselegiline as the HC1 in sufficient 0.9% isotonic saline solution to provide a final volume of 100 ml.
  • the solution is buffered to pH 4 with citric acid, sealed, and sterilized to provide a 1% solution suitable for intravenous administration in the treatment of conditions produced by neuronal degeneration or neuronal trauma.
  • Tablets and capsules containing desmethylselegiline are prepared from the following ingredients (mg/unit dose): desmethylselegiline 1-5 microcrystalline cellulose 86 lactose 41.6 citric acid 0.5-2 sodium citrate 0.1-2 magnesium stearate 0.4 with an approximately 1: 1 ratio of citric acid and sodium citrate.
  • a patient with breast cancer will be treated with a pharmaceutical composition that includes R(-)DMS, S(+)DMS, or a mixture of both (10 mg per day), as well as paclitaxel, by intravenous administration.
  • Paclitaxel will be administered at a dose of 175 mg/m over a period of 3 hours. Treatment will be repeated every 3 weeks for a total often cycles. Administration of R(- )DMS, S(+)DMS, or the mixture of both may be continued for at least one month after freatment with paclitaxel ends.
  • a physician will evaluate tumor response and reoccurrence in the patient on a weekly, monthly, or yearly basis.
  • patients at risk for developing breast cancer due to family history, genotype, age, or previous occurrence will be treated with a pharmaceutical composition that includes R(-)DMS, S(+)DMS, or amixture of both R(-)DMS and S(+)DMS.
  • R(-)DMS, S(+)DMS, or a mixture of both is administered to a patient at risk for breast cancer via a transdermal patch at a delivered dose of about 0.05 to 0.10 mg/kg per day for an extended period of time.
  • the preventive therapy utilizing DMS may be continued for months or years, depending on the risk factors for the patient, including age.
  • compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents that are chemically or physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet le traitement des maladies ou états néoplasiques par l'administration de R(-) desméthylsélégiline, S(+) desméthylsélégiline, ou d'une combinaison des deux. Les maladies et états néoplasiques qui réagissent bien à R(-) desméthylsélégiline et/ou S(+) desméthylsélégiline comprennent aussi bien les néoplasmes cancéreux que les néoplasmes bénins.
PCT/US2001/026658 2000-08-28 2001-08-27 Procedes et compositions pharmaceutiques utilisant la desmethylselegiline pour traiter des maladies ou des etats neoplasiques WO2002019964A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002420993A CA2420993A1 (fr) 2000-08-28 2001-08-27 Procedes et compositions pharmaceutiques utilisant la desmethylselegiline pour traiter des maladies ou des etats neoplasiques
AU8679801A AU8679801A (en) 2000-08-28 2001-08-27 Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
AU2001286798A AU2001286798B2 (en) 2000-08-28 2001-08-27 Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22843100P 2000-08-28 2000-08-28
US60/228,431 2000-08-28

Publications (2)

Publication Number Publication Date
WO2002019964A2 true WO2002019964A2 (fr) 2002-03-14
WO2002019964A3 WO2002019964A3 (fr) 2003-02-27

Family

ID=22857139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/026658 WO2002019964A2 (fr) 2000-08-28 2001-08-27 Procedes et compositions pharmaceutiques utilisant la desmethylselegiline pour traiter des maladies ou des etats neoplasiques

Country Status (3)

Country Link
AU (2) AU8679801A (fr)
CA (1) CA2420993A1 (fr)
WO (1) WO2002019964A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1704859A1 (fr) * 2005-02-18 2006-09-27 Universitätsklinikum Freiburg Contrôle de l'expression génique dépendante du recepteur androgénique par inhibition de l'activité monoamine oxidase de la démethylase spécifique de la lysine (LSD1)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3036847B2 (ja) * 1995-01-13 2000-04-24 サマーセット・ファーマシューティカルズ・インコーポレイテッド デスメチルセレギリンを用いる方法および医薬組成物
US6319954B1 (en) * 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6299901B1 (en) * 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6033682A (en) * 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6417160B1 (en) * 1997-10-14 2002-07-09 Nadine A. Tatton Methods for increasing schwann cell survival
AU1956399A (en) * 1998-01-13 1999-08-02 University Of Saskatchewan Technologies Inc. Composition containing propargylamine for enhancing cancer therapy
US20020137786A1 (en) * 1998-02-12 2002-09-26 William G. Tatton Deprenyl compounds to treat viral infections and reduce tissue damage associated therewith
BR9908713A (pt) * 1998-03-16 2000-11-21 Somerset Pharmaceuticals Inc Uso de selegilina ou desmetil-selegilina para tratamento de feridas, queimaduras e danos dermatológicos

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1704859A1 (fr) * 2005-02-18 2006-09-27 Universitätsklinikum Freiburg Contrôle de l'expression génique dépendante du recepteur androgénique par inhibition de l'activité monoamine oxidase de la démethylase spécifique de la lysine (LSD1)
WO2006087206A3 (fr) * 2005-02-18 2006-11-30 Universitaetsklinikum Freiburg Regulation de l'expression genique dependante du recepteur d'androgene
US8680157B2 (en) 2005-02-18 2014-03-25 Universitaetsklinikum Freiburg Androgen receptor-dependent gene expression control
US9370499B2 (en) 2005-02-18 2016-06-21 Universitaetsklinikum Freiburg Androgen receptor-dependent gene expression control

Also Published As

Publication number Publication date
CA2420993A1 (fr) 2002-03-14
AU8679801A (en) 2002-03-22
AU2001286798B2 (en) 2007-05-17
WO2002019964A3 (fr) 2003-02-27

Similar Documents

Publication Publication Date Title
KR100236666B1 (ko) 트라마돌 및 코데인, 옥시코돈 또는 하이드로코돈을 함유하는 조성물 및 그의 용도
US6562365B2 (en) Methods employing R(−)-desmethylselegiline
US6255329B1 (en) Combined use of pramipexole and sertraline for the treatment of depression
US6528082B2 (en) Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
CZ187097A3 (cs) Farmaceutický prostředek
KR102372194B1 (ko) Lsd1 억제제를 이용한 다발성 경화증의 치료방법
KR20060109493A (ko) 비만을 치료하기 위한 조합 약물 치료
CN100360123C (zh) 应用去甲司来吉兰的方法和医药组合物
JP3470901B2 (ja) Ｅｌｆ５Ａ生合成の抑制方法
US6562364B2 (en) Desmethylselegiline enantiomers and their use to treat drug withdrawal symptoms
AU2001286798B2 (en) Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
US6319954B1 (en) S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
AU2001286798A1 (en) Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
Zhu et al. Chronic imipramine treatment downregulates IR1-imidazoline receptors in rat brainstem
JP2005525377A (ja) デスメチルセレジリンの投与による末梢神経障害の予防および処置のための方法
US20030191191A1 (en) Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline delivery compositions
AU2003220016B2 (en) Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline
AU9736301A (en) Methods and pharmaceutical compositions employing desmethylselegiline enantiomers
AU2004202529A1 (en) Methods and pharmaceutical compositions employing desmethylselegiline enantiomers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2420993

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001286798

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001286798

Country of ref document: AU

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载